The PII protein, encoded by glnB, is known to interact with three bifunctional signal transducing enzymes (uridylyltransferase/uridylyl-removing enzyme, adenylyltransferase, and the kinase/phosphatase nitrogen regulator II [NRII or NtrB]) and three small-molecule effectors, glutamate, 2-ketoglutarate, and ATP. We constructed 15 conservative alterations of PII by site-specific mutagenesis of glnB and also isolated three random glnB mutants affecting nitrogen regulation. The abilities of the 18 altered PII proteins to interact with the PII receptors and the small-molecule effectors 2-ketoglutarate and ATP were examined by using purified components. Results with certain mutants suggested that the specificity for the various protein receptors was altered; other mutations affected the interaction with all three receptors and the small-molecule effectors to various extents. The apex of the large solvent-exposed T loop of the PII protein (P. Escherichia coli and related bacteria regulate the activity of glutamine synthetase (GS) in at least three ways (reviewed in references 24, 33, 36, and 42-44). GS is subjected to concerted feedback inhibition by several metabolic intermediates (27). Also, the activity of GS is regulated by reversible adenylylation, catalyzed by adenylyltransferase (ATase), with the adenylylated form of GS being less active. Finally, the biosynthesis of GS is regulated by the control of the initiation of transcription of its structural gene, glnA. These regulatory mechanisms enable the cell to rapidly adjust GS activity in response to changes in the availability of the preferred nitrogen source, ammonia. When nitrogen is in excess, cells contain little GS and the enzyme is mostly adenylylated; under conditions of nitrogen limitation, the intracellular concentration of GS is 7-to 10-fold higher and the enzyme is mostly unadenylylated. Under the latter conditions, the reaction catalyzed by GS constitutes the major route for the assimilation of ammonia.
Escherichia coli and related bacteria regulate the activity of glutamine synthetase (GS) in at least three ways (reviewed in references 24, 33, 36, and 42-44) . GS is subjected to concerted feedback inhibition by several metabolic intermediates (27) . Also, the activity of GS is regulated by reversible adenylylation, catalyzed by adenylyltransferase (ATase), with the adenylylated form of GS being less active. Finally, the biosynthesis of GS is regulated by the control of the initiation of transcription of its structural gene, glnA. These regulatory mechanisms enable the cell to rapidly adjust GS activity in response to changes in the availability of the preferred nitrogen source, ammonia. When nitrogen is in excess, cells contain little GS and the enzyme is mostly adenylylated; under conditions of nitrogen limitation, the intracellular concentration of GS is 7-to 10-fold higher and the enzyme is mostly unadenylylated. Under the latter conditions, the reaction catalyzed by GS constitutes the major route for the assimilation of ammonia.
Nitrogen regulation of the transcription of glnA and certain other genes results from the action of the two-component regulatory system consisting of the bifunctional histidine protein kinase/phosphoprotein phosphatase nitrogen regulator II (NRII or NtrB, the product of glnL or ntrB) and the response regulator nitrogen regulator I (NRI or NtrC, the product of glnG or ntrC) (reviewed in references 24, 33, and 36) . NRII controls the intracellular concentration of the phosphorylated form of NRI, NRIϳP; NRIϳP is an enhancer-binding transcriptional activator of RNA polymerase containing the minor sigma factor 54 . This activator stimulates transcription of glnA and certain other nitrogen-regulated genes and also acts to repress gene transcription (40, 41) .
The regulation of ATase and the nitrogen regulation of gene transcription by NRI and NRII utilize a common sensory and signal transduction system consisting of the uridylyltransferase/ uridylyl-removing enzyme (UTase/UR, the product of glnD) and the PII protein (the product of glnB) ( Fig. 1) (1, 3, 7-10, 12, 14, 15, 22, 28, 34, 48, 50 ; reviewed in references 33, 44, and 49) . These proteins are apparently present continuously in E. coli (50) , but some evidence for regulation of the very low level of glnD transcription has been presented (22, 44) . In addition, E. coli contains a gene encoding a homolog of PII (2, 51, 52) , named GlnK, whose expression is nitrogen regulated and which was detectable only in nitrogen-starved cells (52) . The presence of the GlnK protein may explain the incomplete derepression of the Ntr system observed in strains with both glnD and glnB, the latter of which encodes PII (8, 24) , deleted. UTase/UR and the PII protein (and presumably, the GlnK protein) respond to small-molecule signals of nitrogen status in vivo such that under nitrogen-limiting conditions PII is uridylylated and under conditions of nitrogen excess PII is unmodified (reviewed in references 33, 44, and 49) . PII and PII-UMP then communicate conditions of nitrogen sufficiency or limitation, respectively, to the PII receptors ATase and NRII (Fig.  1) . In vitro, 2-ketoglutarate and ATP are activators of the UTase activity, which is inhibited by glutamine (1, 12, 22, 43 ; also unpublished data). The physiologically relevant Mg 2ϩ -dependent uridylyl-removing activity of UTase/UR is activated by glutamine, 2-ketoglutarate, and ATP (1, 12 ; also unpublished data). However, since the concentrations of 2-ketoglutarate and ATP required to activate the UTase and UR activ-ities are well below their reported in vivo concentrations, the UTase/UR-PII monocycle is mainly a glutamine-sensing apparatus (unpublished data).
Both PII and PII-UMP interact with the bifunctional ATase. PII activates the adenylylation activity of the ATase; this activity is also activated independently and additively by glutamine. In addition, PII weakly inhibits the deadenylylation activity of ATase. Conversely, PII-UMP is an essential activator of the ATase deadenylylation activity, which also is activated independently by 2-ketoglutarate at concentrations similar to the reported in vivo concentration of 2-ketoglutarate. Thus, PII and glutamine stimulate the inactivation of GS, and PII-UMP and 2-ketoglutarate stimulate the activation of inactive GS by the ATase (reviewed in references 42, 44, and 49) .
PII, but not PII-UMP, interacts with NRII (3). In the absence of PII, NRII binds ATP and phosphorylates itself on a conserved histidine residue (37, 39, 53) , and these phosphoryl groups are then transferred to a conserved aspartate residue in the N-terminal domain of NRI in a reaction that is probably catalyzed by the N-terminal domain of NRI (53; reviewed in reference 36). NRI is also phosphorylated by transfer of the phosphoryl group from the metabolic intermediate acetyl phosphate (13) (Fig. 1) . Neither the rate of autophosphorylation of NRII nor the rate of phosphotransfer from NRIIϳP to NRI was greatly affected by PII (22) . However, the addition of PII to reaction mixtures containing NRI, NRIϳP, NRII, and ATP resulted in the rapid dephosphorylation of NRI (22, 26, 38) . This activity seems to be responsible for the ability of NRII to prevent transcription of nitrogen-regulated genes under conditions of nitrogen excess (38) ; it is referred to as the regulated phosphatase activity (26) and occurs by an unknown mechanism. PII is not itself a phosphatase (22, 38) , and genetic and some biochemical evidence suggest that it acts to stimulate an activity of NRII (4, 5, 8, 21) . This activity is also stimulated by ATP (21, 26) . Mutant forms of NRII lacking this activity or demonstrating a similar ATP-stimulated activity in the absence of PII have been identified (5, 21) . The histidine residue that serves as the site of NRII autophosphorylation is apparently not required for the regulated phosphatase activity (5, 21) , and the product of the reaction is inorganic phosphate (53) . Thus the phosphatase activity is not the reversal of the phosphotransfer reaction. However, many mutations apparently affecting this activity map adjacent to the NRII active-site histidine (4, 31, 32) , and thus these mutations may affect the interaction of NRII with NRI and NRIϳP.
The ability of PII to stimulate the regulated phosphatase activity of NRII and to be uridylylated and deuridylylated by the UTase/UR is dramatically regulated by small-molecule effectors that bind to PII (23, 29) . ATP and 2-ketoglutarate were required to detect the binding of NRII to PII, by an affinity chromatography method (23) , and to detect uridylylation and deuridylylation of the PII protein; these effectors also dramatically stimulate the regulated phosphatase activity (23) . The concentrations of 2-ketoglutarate and ATP required to activate the UTase and UR activities (ϳ7 and 20 M) were similar to the concentration at which activation of the regulated phosphatase activity occurred (23) , but the ATP constant was higher than the reported dissociation constant from direct measurements (1.5 M [23] ). We show elsewhere that when more-extensive binding experiments were performed under conditions identical to those for the experiments described in this paper, the binding of 2-ketoglutarate and ATP was cooperative and that in the presence of saturating concentrations of the other effector, the constants were ϳ5 and 20 M, respectively (unpublished data). Thus, we expect that in vivo, where the ATP and 2-ketoglutarate concentrations are ϳ3 and 0.1 to 0.9 mM, respectively (46) , virtually all of the PII population is bound by these effectors.
Other small-molecule effectors may simulate some of the effects of 2-ketoglutarate in vitro. Glutamate, oxaloacetate, or 3-ketoglutarate, when combined with ATP, could activate the PII-dependent regulated phosphatase activity (K act from 50 M to Ͼ50 mM [22, 27] ), but 2-ketoglutarate was by far the most effective. These effectors appear to bind the same site on PII as 2-ketoglutarate, since the ability of the various effectors to activate the regulated phosphatase activity was similar to the effectiveness in competing with 2-ketoglutarate for binding to PII (23) . However, only ketoglutarate could activate the uridylylation of PII, and glutamate, even at a very high concentration, could not detectably inhibit this reaction. Thus, based on the in vivo concentrations and the relative affinity of these effectors for PII, it doesn't seem likely that these effectors have a role in regulating PII activity in vivo. However, a curious effect of high 2-ketoglutarate was observed in the regulated phosphatase assay: high 2-ketoglutarate (Ͼ5 mM) inhibited (29) or was not as effective as a low 2-ketoglutarate concentration (50 M) in stimulating (23) the ability of PII to activate the regulated phosphatase activity. The reason for this effect is not known.
PII proteins have been identified in a wide range of bacteria, and comparison of the conceptual translation products from the DNA sequences reveals two highly conserved regions of primary sequence. The SWISS-PROT protein signatures for these two regions are shown in Fig. 2 (SWISS-PROT annotations to the Escherichia coli glnB file); all PII proteins from eubacteria contain these signatures, and no other protein sequences in the SWISS-PROT database match these signatures. In this report, the results of alteration of 8 of the 20 sites contained within the protein signatures are presented.
The structure of the E. coli PII protein is known to high resolution (9, 10) . The 112-amino-acid PII protein forms a homotrimer, with each monomer consisting of six ␤-strands and two ␣-helices. The monomer can be divided into three sections: a central core with a protruding 8-residue loop designated the B-loop, a large 19-residue loop, designated the T-loop, at one end, and a small, 4-residue loop, designated the C-loop, at the other end ( Fig. 3) (9, 10) . The central section consists of a four-stranded ␤-sheet mostly facing the interior of the trimer and the two ␣-helices. The T-loop contains the site of PII uridylylation, and protrudes ϳ15 Å from the central section. The C-loop is stabilized by two short ␤-strands (␤5 and ␤6) and is located at the opposite end of the molecule. In the trimer, the B-loop from one subunit lies near the C-loop of an adjacent subunit, such that the external surface of the trimer contains three clefts lined mostly by residues in the B-and C-loops; one side of the clefts is lined with basic residues (R38, K40, K85, and K90 from one subunit and R101 and R103 from another), while the other side is uncharged (9, 10) . Given the proximity of these clefts to the site of PII uridylylation, they have been implicated as the site of important regulatory interactions, such as those with small-molecule effectors and/or protein receptors (9, 10) . In the work reported here, we examined this hypothesis by analyzing the effect of conservative alterations of residues R38, K40, and K90 and the nearby residue G89 on the interaction of PII with its three protein receptors and small-molecule effectors. We also examined the effect of altering residue G84 in the B-loop and nearby residue R79, on the exterior surface of ␣B. In addition, we used the known structure of PII to design an altered PII with a deletion of the apex of the large loop (⌬47-53). Finally, note that the trimeric PII contains a central channel; the side chains pointing into this channel are charged (K5, D3, E62, K60), while the side chains lining the rims of the central channel are mainly hydrophobic (V33 in ␤2 and F94 in ␤4).
We also chose to alter the site of PII uridylylation at Y51, as well as at the nearby Y46. This was done for two reasons; we desired a PII that could not be uridylylated for kinetic studies, and we wanted to see if the nearby Y46 or any other site on PII or UTase/UR could be uridylylated in the absence of the usual site of uridylylation. We altered residue E50, adjacent to the site of uridylylation, because a mutation at this site in the closely related Klebsiella pneumoniae PII protein had been studied in intact cells; the phenotype of the mutant cells suggested that the mutant PII could not be uridylylated (18) .
Finally, we were interested in whether the interaction of PII with its three protein receptors was genetically separable; that is, are the same surface features of PII recognized by UTase/ UR, NRII, and ATase? The presence of multiple PII proteins in E. coli (52) and in other bacteria (11) and the apparent presence of a single UTase/UR enzyme raise the possibility that under conditions under which both PII proteins are present, UTase/UR may separately control the activity of NRII and the ATase via distinct PII proteins. UTase/UR and ATase share a conserved sequence element found in other nucleotidyltransferase proteins (17) ; however, there is no recognizable sequence similarity between either of these two enzymes and NRII. In this work we report the isolation of a mutant form of PII that was selected as unable to interact with NRII, A49P, and two mutant forms of PII that were selected as defective in the interaction with UTase/UR, T29M and T83N.
Thus, altered PII proteins were constructed or isolated for a variety of reasons. In this study, we characterized the interaction of each of the altered PII proteins in assays with the purified PII receptors and examined directly the binding of the small- Coloring is as follows: yellow, ␤1; cyan, ␣A; orange, ␤2; green-blue, T-loop; red, ␤3; green, ␣B; blue, B-loop; magenta, 4; red-orange, ␤5; lavender, C-loop; and violet, ␤6. In the space-filling models, the sites altered in this study and other landmark sites are depicted in Corey-Paulin-Koltur coloring (grey, carbon; light blue, nitrogen; and red, oxygen) to facilitate the visualization of side chains. Landmark sites marked on the figure but not studied in this work are R101 and R103, which line the cleft between B-and C-loops (from reference 10); E62, K3, D5, and K60, which line the central channel (from reference 9); V33 and F94, which form the top and bottom "caps" respectively of the central channel (from reference 9); and C73, a unique cysteine near the surface of PII. molecule effectors ATP and 2-ketoglutarate. In an accompanying study (19) , we constructed heterotrimers containing wild-type and mutant PII subunits and studied their properties.
MATERIALS AND METHODS
Strategy for the isolation of random glnB mutations. We constructed an altered glnB gene in which the coding sequence was unchanged but restriction sites were introduced within the flanking regions so as to facilitate subcloning into a number of vectors. Unique flanking 5Ј EcoRI and NdeI sites and a unique flanking 3Ј BamHI site were introduced by PCR amplification using the following primers: 5Ј-CCCGAATTCATATGAAAAAGATTGATGCGATT-3Ј (upstream primer) and 5Ј-GGGGATCCGCGGCCCGGTTGGCAACATGC-3Ј (downstream primer). These primers anneal to the first 21 nucleotides of the coding region and nucleotides 132 to 153 downstream from the glnB coding region. The amplified glnB gene was cleaved with EcoRI and BamHI and subcloned into similarly digested pAlter-1 (Promega). Nucleotide sequencing confirmed that the coding sequence was wild type after these manipulations. The glnB fragment was then subcloned into the pBR322, pUC18, and pJLA503 vectors (35, 35a, 45) , and the complementation of a strain with glnB deleted was examined. By comparison with previous results (4, 8) , it appeared that the promoterless pBR322-based construct programs the expression of a lower concentration of PII than does the single chromosomal copy; for example, the wild-type glnB allele on the pBR322-based construct provided incomplete complementation of a chromosomal ⌬glnB (data not shown). In contrast, the pUC18-based construct, in which the plasmidborne lac promoter drives glnB expression, resulted in the vast overproduction of PII as deduced in two ways: first, upon introduction into a ⌬glnB strain, the negative regulation of GS biosynthesis was more effective than that seen in the wild-type strain, and second, examination of crude extracts by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie brilliant blue R-250 staining revealed a prominent band corresponding to the overexpressed PII protein (data not shown). The pJLA503-based construct, which complemented the ⌬glnB strain very poorly under noninducing conditions (data not shown), resulted in even higher levels of PII overproduction upon induction, as previously described (22), and these constructions were used to purify the altered PII proteins.
Selection scheme for mutations in glnB affecting the regulation of glnA transcription. Random mutagenesis of glnB was performed by amplification of a restriction fragment containing glnB by mutagenic PCR (see below). The amplification product was then cloned into pUC18 and introduced into a ⌬glnB strain that also contained the lacZ15 mutation and thus produced the lacZ ␣ peptide (RB9060Q) (see below). Transformants that contained plasmids with a glnB fragment were identified by blue-white screening as white colonies on rich medium indicator plates containing ampicillin and X-Gal (5-bromo-4-chloro-3-indolyl-␤-D-galactopyranoside), and plasmids with mutations affecting nitrogen regulation were obtained by screening transformants for those that resulted in altered regulation of GS, compared to strains containing the analogous unmutagenized pUC18-glnB ϩ construct. For this, the previously described GS microassay was used with cells grown in small patches on solid defined medium (4) . Since the pUC18-based plasmids result in the vast overproduction of PII, screens using this vector are likely to reveal only altered PII proteins with dramatic differences in PII activity. One of the mutations, which later proved to cause alteration of Ala 49 to Pro, was initially identified as lacking the ability to bring about the negative regulation of GS on nitrogen-rich medium. Two other mutations, which proved to be due to the alteration of Thr 29 to Met and Thr 83 to Asn, were initially identified as causing the repression of GS under nitrogenlimiting conditions. The mutant alleles were completely sequenced directly from the pUC18-based plasmids with a Sequenase kit (U.S. Biochemicals) as described previously (16) .
PCR mutagenesis of glnB. The 5Ј and 3Ј primers noted above were used, and the amplification conditions were as follows: 5 mM Tris-Cl (pH 8.75), 10 mM KCl, 10 mM (NH 4 ) 2 SO 4 , 2 mM MgSO 4 , 0.1% Triton X-100, bovine serum albumin (0.1 mg/ml, 5 or 7.5 mM MgCl 2 , and 5 U of Taq DNA polymerase [Bethesda Research Laboratories]). The thermal cycling program was 95°C for 30 s, 60°C for 30 s, and 72°C for 2 min; 30 cycles were performed, followed by a final incubation at 72°C for 10 min. The amplification product was digested with EcoRI and BamHI, cloned into similarly cleaved pUC18, and transformed into strain RB9060Q (⌬glnB FЈ lacI q lacZ15) by standard procedures (35) . Construction of strain RB9060Q. Strains RB9060 (⌬glnB) and the related strain BA (⌬glnB glnA::Tn5) each contain a deletion of the glnB gene (4, 8) but lack the lacZ ␣ peptide and thus are not suitable for blue-white screening of ligation products on indicator media containing X-Gal. FЈ lacZ15 Tn10 (Tet r ) was introduced into RB9060 from strain XL1-Blue (Promega) in two steps. First, XL1-Blue was mated with strain BA, with selection on Luria-Bertani-glutaminekanamycin-tetracycline plates. This was necessary to move the FЈ into a strain that could be counterselected by a nutritional marker; the BA strain was chosen from our collection simply because it bears the convenient Kan r marker and is a glutamine auxotroph. The exconjugant strain, BAQ (glnA::Tn5 ⌬glnB FЈ lacI q lacZ15 Tet r ), was then mated with RB9060, with selection on minimal glucoseammonia-tetracycline medium. An exconjugant bearing the glnB deletion and FЈ (lacI q lacZ15 Tet r ) was designated RB9060Q.
Site-specific mutagenesis of glnB. Site-specific mutations were introduced into the glnB gene by oligonucleotide-based mutagenesis with the Altered Sites mutagenesis kit (Promega), used according to the manufacturer's directions. After the point or deletion mutants were constructed, the entire coding region of each mutant glnB was sequenced with a Sequenase kit (U.S. Biochemicals) to ensure that only the designed mutations were introduced. The mutagenic primers used are listed in Table 1 .
Purification of altered PII proteins. Mutant glnB alleles were digested with NdeI and BamHI and subcloned into similarly cleaved pJLA503 to create overproduction plasmids similar to the previously described pBOP plasmid (22) . These plasmids were transformed into strain BD (⌬glnB glnD99::Tn10), with selection for ampicillin resistance, and were grown and induced in the very nitrogen-rich Luria-Bertani-glutamine medium as described previously (22) . The efficiency of the overproduction of each PII protein was verified in small-scale fermentations as before (22); each of the altered PII proteins was greatly overproduced in this vector system (data not shown). Purification of the altered PII proteins from 4 liters of induced culture was as described previously (22) ; briefly, this involved ammonium sulfate fractionation and chromatography on DE52, Sephadex G-75, and hydroxylapatite. The purity of these protein preparations was verified by nondenaturing PAGE (3) and by SDS-PAGE (47) and Coomassie brilliant blue staining. Protein concentrations were determined by the method of Lowry et al. (30) . Typical yields of ϳ100 mg of purified PII were obtained.
Uridylylation of PII. UTase/UR was purified, quantified, and stored as described previously (3, 22) . Uridylylation of PII by the UTase/UR enzyme was assayed essentially as before (22, 23) ; reaction conditions were as follows: 10 M PII or altered PII protein, 50 mM Tris-Cl (pH 7.5), 100 mM KCl, 10 mM MgCl 2 , 1 mM dithiothreitol (DTT), 0.5 mM ATP, 33 M 2-ketoglutarate, and 0.066 M UTase/UR. After preincubation at 30°C for 2 min, [␣-32 P]UTP was added to 0.5 mM to initiate the reaction, and aliquots were spotted at time intervals onto nitrocellulose filters and washed in 5% trichloroacetic acid (TCA) to remove unincorporated UTP. After the filters had dried in air, their radioactivity was counted by liquid scintillation. Initial rates were determined in two ways. The data points were fitted to the first-order rate equation by using the Enzfit program, and the equation was solved for t ϭ 0. Additionally, initial rates were manually estimated after plotting by hand. Both methods resulted in similar estimates of the initial rates; the values shown in Table 2 are from the Enzfit fitting. In all experiments, wild-type PII was assayed for comparison purposes, and the results are expressed as relative initial rates. The variation in the initial rate of uridylylation of the wild type from experiment to experiment was generally less than 30%.
Nondenaturing 16% PAGE analysis of the uridylylation and deuridylylation of PII was conducted as described previously (3) . Briefly, the reaction mixtures contained 100 mM Tris-Cl (pH 7.5), 100 mM KCl, 50 mM MgCl 2 , 1 mM DTT, 500 M ATP, wild-type or mutant PII (as indicated) (10 M), UTase/UR (200 nM), UTP (500 M), and 2-ketoglutarate (33 M). Reaction mixtures lacking UTP were incubated for 2 min at 30°C, 5-l aliquots were removed prior to the addition of UTP (zero time samples), and uridylylation was initiated by the addition of UTP. Aliquots (5 l) were then removed at 2, 5, 10, 15, and 20 min, as indicated, after which glutamine was added to 2 mM. After an additional 15 or 20 min of incubation, as indicated, another 5-l aliquot was removed. The samples were adjusted to 30 mM EDTA to stop the reaction upon removal from the reaction mixture and held on ice until all samples had been gathered, after which the gels were run and stained with Coomassie brilliant blue.
The apparent K m and rate constant (k cat ) for the E50Q-altered PII protein were determined by measuring the initial rate of PII uridylylation in reaction mixtures containing 50 mM Tris-Cl (pH 7.5), 100 mM KCl, 25 mM MgCl 2 , 1 mM DTT, 0.5 mM ATP, 33 M 2-ketoglutarate, bovine serum albumin (300 g/ml), 40 M [␣-32 P]UTP, and 4 nM UTase/UR enzyme. Five different concentrations of the E50Q protein were used: 1.5, 2.5, 3.5, 6, and 15 M. Initial rates were estimated by using the Enzfit program as described above.
The abilities of altered PII proteins to inhibit the uridylylation of wild-type PII were determined by measuring the initial rate of PII uridylylation in reaction mixtures similar to those described above for the K m determination of the E50Q protein and containing wild-type PII (1.5 M), altered PII protein (10 M), UTP (50 M), and the UTase/UR enzyme (4 nM). Initial rates were estimated by using the Enzfit program.
Adenylylation of GS. ATase was purified from cultures containing pMR207, kindly provided by W. van Heeswijk, by a method similar to that devised by van Heeswijk and colleagues (52) . Briefly, the purification involved ammonium sulfate precipitation at 45% saturation, chromatography on a QA52 column (Whatman), and gel filtration on BioGel A1.5M (Bio-Rad). Typical yields were 70 mg/4 liters of induced culture. GS was purified by Zn 2ϩ precipitation as described previously (41) . ATase and GS concentrations were determined by the method of Lowry et al. (30) . Adenylylation assays were performed as follows. Reaction mixtures containing 1 M GS dodecamer, 50 mM Tris-Cl (pH 7.5), 25 mM MgCl 2 , 5 mM glutamine, 5 nM ATase, and either 400 nM PII, 400 nM altered PII protein, or a similar concentration of PII storage buffer (as a control) were incubated at 30°C. The reactions were initiated by the addition of 0.5 mM [␣-
32 P]ATP, aliquots were removed at 1-min intervals and spotted onto nitrocellulose filters, and TCA-precipitable radioactivity was measured by liquid scintillation. All initial rates were corrected by subtraction of the rate of adenylylation observed in the absence of PII, and the results are expressed in Table 2 as relative to the rate of adenylylation stimulated by the wild-type PII protein.
Phosphorylation assays. NRI and NRII were purified, quantitated, and stored as described previously (22, 40) . NRI phosphorylation and dephosphorylation by NRII and PII was assayed as before (3, 22, 38) . Briefly, NRI (18 M) was phosphorylated by incubating at 25°C with NRII (0.3 M) in a reaction mixture containing 50 mM Tris-Cl (pH 7.5), 100 mM KCl, 10 mM MgCl 2 , 50 M 2-ketoglutarate, and 0.6 mM [␥-
32 P]ATP. After 20 min of incubation, wild-type or mutant PII was added to either 0.3 or 3 M, and the extent of NRI phosphorylation was assessed by spotting aliquots of the reaction mix onto nitrocellulose filters at indicated time intervals and counting the TCA-precipitable radioactivity by liquid scintillation. In each experiment, the wild-type PII protein was included as a control, and results are expressed as relative initial rates of NRIϳP dephosphorylation after the addition of PII. These rates were estimated as described above.
Binding of ATP and 2-ketoglutarate to PII proteins. Binding of PII to its small-molecule ligands was assessed by the ultrafiltration method described previously (23) . For ATP binding, 10 M wild-type or mutant PII was incubated with 50 mM Tris-Cl (pH 7.5), 100 mM KCl, 10 mM MgCl 2 and 2 M [ 14 C]ATP in the absence or presence of 1 mM 2-ketoglutarate. After incubation at 25°C for 30 min, samples were withdrawn for measurement of total (bound plus free) ligand. The remaining samples were transferred to Microcon-P10 filtration units (Amicon) and centrifuged at 4,000 rpm in an Eppendorf centrifuge (model 5415C) for about 14 min (until a passage of approximately half the volume of the samples was achieved). Samples from the receiving chamber were used for measuring the free ligand. The concentration of bound ligand was derived by subtracting the free ligand from total ligand. In the cases of 2-ketoglutarate binding, the conditions were similar except that 2 mM ATP was included and 
RESULTS
Isolation or construction of glnB mutants and purification of altered PII proteins. PII proteins from various organisms share two highly conserved segments of primary sequence (Fig.  2) . The roles of these conserved sequences were examined directly by constructing mutations encoding conservative amino acid replacements at the indicated sites within these conserved regions (Fig. 2 and 3 ). In addition, based on the known structure of PII, residues R38, K40, and K90 were predicted to be involved in regulatory interactions (9, 10), and these and the nearby G89 were altered with conservative amino acid replacements by site-specific mutagenesis ( Fig. 2  and 3 ). Finally, glnB mutations resulting in altered regulation of GS were isolated after random mutagenesis (Materials and Methods). The altered proteins encoded by the mutant glnB alleles were then purified by the standard procedure used to obtain wild-type PII. A list of the 18 mutant proteins obtained and a summary of their characteristics are presented in Table  2 . All of the proteins used in this study behaved as did the wild type throughout the purification procedure. Denaturing (SDS) PAGE (47) was used to verify the purity of each protein preparation, and nondenaturing polyacrylamide gel electrophoresis was used to determine whether the altered PII proteins form the normal homotrimer. The purified PII proteins were each about 85 to 90% pure (data not shown) and nondenaturing gel electrophoresis indicated that most of the purified PII proteins had a mobility similar to wild-type PII (data not shown), indicating a trimeric structure. The Q39E, K40N, R38H, R79H, and ⌬47-53 proteins reproducibly had a mobility slightly higher than that of the wild-type protein, while the E50Q and T29M proteins had mobilities slightly lower than that of the wild-type protein on nondenaturing gels (data not shown). Of these, the difference in mobility of the Q39E, K40N, and E50Q proteins is likely to be due, at least in part, to the change in charge introduced by the alteration. To demonstrate that these proteins were indeed trimeric, the time course of uridylylation of the wild-type and the R79H, R38H, and K40N proteins was monitored by nondenaturing gel electrophoresis. Previous results indicated that the wild-type PII exists in four states, corresponding to the unmodified protein and proteins containing one, two, or three uridylyl groups, and that each of these forms may be observed on nondenaturing gels (3). A similar analysis of the three mutant forms examined suggested that these proteins formed trimers (data not shown). The truncated protein ⌬47-53 is also likely to form trimers; although this protein could not be uridylylated (see below) and therefore could not be examined as described above, its mobility on nondenaturing gels is considerably lower than that of the monomeric form of the N-terminal domain of NRI, which has a molecular mass of ϳ18,000 Da (data not shown). Thus, none of the alterations listed in Table 2 appear to have prevented the formation of the normal homotrimer.
Uridylylation of altered PII proteins by UTase/UR. The ability of each altered PII protein to become uridylylated under a standardized set of conditions was measured (Materials and Methods). In each experiment, wild-type PII was included as a control, and the results are expressed as initial rates of uridylylation relative to that of the wild type. This assay was observed to be highly reproducible both when multiple tests of the same sample were run in a single assay and when assays performed on different days were compared. A typical uridylylation assay is shown in Fig. 4A , and data for the complete set of altered proteins is presented in Table 2 . As indicated, the Y51F, Y51F Y46F, G89A, and ⌬47-53 proteins were not detectably uridylylated. The T29M, Q39E, G41A, E50Q, V53G, K90R, and T83N proteins were also severely defective in the ability to become uridylylated by the UTase/UR (Table 2) . Conversely, the A49P, R79H, and G84A mutations had little effect on the ability of PII to be uridylylated by UTase/UR.
We conducted several additional studies to examine whether altered forms of PII that were defective in uridylylation by UTase/UR were able to interact with the enzyme. We have previously observed that the UTase/UR enzyme has an apparent K m for wild-type PII of ϳ3.0 M and a k cat of ϳ60.5 min
Ϫ1
when UTP was present at 40 M (unpublished data). By similar methods, the K m for the E50Q protein was observed to be 3.59 M, but the k cat was observed to be only 6.2 min Ϫ1 (data not shown). That is, the E50Q protein was not defective in the interaction with the enzyme but was strongly defective in the catalytic step.
The ability of the Y51F, Y51F Y46F, G89A, and ⌬47-53 altered PII proteins to inhibit the uridylylation of wild-type PII by the UTase/UR was measured (Fig. 5) . In these experiments, the wild-type PII was present at 1.5 M, and the competing altered PII protein was present at 10 M. As shown, the G89A and ⌬47-53 altered PII proteins provided little inhibition of the uridylylation of wild-type PII, suggesting that they do not interact with the enzyme, while the Y51F and Y51F Y46F proteins provided considerable inhibition of the uridylylation of wild-type PII, indicating that these altered PII proteins interact with the enzyme (Fig. 5) .
Stimulation of ATase. ATase catalyzes the adenylylation of GS in the presence of glutamine and ATP, and this reaction is greatly stimulated by PII. We measured the ability of each altered PII protein and wild-type PII to activate the ATase under a standardized set of conditions (Materials and Methods). The results are expressed as ability to stimulate the rate of adenylylation relative to the wild-type PII. A typical adenylylation assay is presented in Fig. 4B , and data for the complete set of altered proteins is presented in Table 2 . Like the UTase assay, this assay is accurate, and its results highly reproducible. As indicated, we were not able to detect activation of ATase by the G37A, T83N, and ⌬47-53 proteins ( Table 2 ). The T29M, K40N, V53G, G84A, and G89A mutations also severely affected the ability of PII to activate ATase. Conversely, the R38H, Q39E, G41A, Y46F, A49P, E50Q, Y51F, and R79H mutations had only a minor effect on the ability of PII to activate the adenylylation activity of the ATase enzyme ( Table  2) .
Stimulation of the regulated phosphatase activity of NRII. The addition of PII to reaction mixtures containing NRI, NRIϳP, NRII, and ATP results in the rapid dephosphorylation of NRIϳP, owing to the activation of the regulated phosphatase activity of NRII. We measured the ability of the altered PII proteins at high (3 M) or low (0.3 M) concentrations to stimulate the rapid dephosphorylation of NRIϳP, using standardized assay conditions in which the small-molecule effector 2-ketoglutarate was present at the optimal concentration (23) . In order to form NRIϳP, NRI was incubated with NRII and ATP for 20 min, by which time the level of phosphorylation of NRI had become constant. PII or an altered PII protein (or buffer control) was then added, and the extent of NRI phosphorylation was periodically monitored. The initial rates of dephosphorylation were determined as described in Materials and Methods and are expressed relative to the wild-type control performed simultaneously in each experiment. Under the conditions used here, 0.3 M wild-type PII was approximately half saturating for the activation of the regulated phosphatase activity, while 3 M PII was saturating (data not shown). Experiments using 3 M PII were therefore the most informative for the unambiguous identification of those PII mutants unable to stimulate the regulated phosphatase activity, while experiments using 0.3 M PII were the best for discerning subtle differences in the activity of the various PII proteins. Raw (unfitted) data from typical experiments in which PII was added to concentrations of 3.0 and 0.3 M are shown in Fig. 4C and D, respectively, and the complete set of data for all of the altered proteins is presented in Table 2 . Unfortunately, this assay is not as reproducible as the UTase and ATase assays described above, in terms of absolute rates of NRIϳP dephosphorylation. On a single day, four separate tests of the wild-type protein resulted in rates differing by Ϯ17%. As indicated in Table 2 , the A49P, G89A, and ⌬47-53 proteins did not activate the regulated phosphatase, even when assayed at 3.0 M. The abilities of G37A, Q39E, K40N, and T29M proteins to activate the regulated phosphatase were also severely affected. In contrast, the K90R, G84A, R79H, V53G, E50Q, G41A, and R38H mutations had little, if any, effect on the ability of PII to activate this activity.
Binding of small-molecule ligands. The ability of PII and the altered PII proteins to bind the small-molecule effectors 2-ketoglutarate and ATP was measured directly as described in Materials and Methods. The binding abilities of altered PII proteins compared to that of the wild-type protein are given in Table 2 . Binding of 2-ketoglutarate was measured in the presence of saturating ATP and in either the absence or presence of excess NRII. Binding of ATP was measured in the absence or presence of saturating 2-ketoglutarate. As indicated, the G89A protein did not bind either ATP or 2-ketoglutarate under all conditions tested ( Table 2 ). The ability of the T29M protein to bind ATP was severely affected; this protein hardly bound ATP at all in the absence of 2-ketoglutarate and was severely defective in ATP binding in the presence of 2-ketoglutarate. The Q39E protein was moderately defective in the binding of ATP, and this binding was slightly stimulated by 2-ketoglutarate. The T83N, G84A, and K90R proteins were moderately defective in ATP binding in the absence of 2-ketoglutarate.
The Q39E protein did not bind 2-ketoglutarate in the absence of NRII but bound this ligand well in the presence of NRII. A similar but less severe defect was seen with the T29M, G37A, and K90R proteins ( Table 2) . 
DISCUSSION
In this work, we describe the use of biochemical assays to probe the effects of mutations in glnB on the known activities of the PII protein. The PII protein was an excellent candidate for such studies since it is small, very stable, and easily purified and the structure of the wild-type protein is known to high resolution. Furthermore, the purified PII receptors are in hand, and while their characterization is ongoing, assays of their activities are available. This direct (biochemical) approach circumvents three problems associated with studying these glnB alleles in vivo. First, the phenotype resulting from complementation of the glnB deletion by plasmids bearing glnB alleles was dependent on the level of expression of the plasmid-borne gene, and none of the plasmid systems we investigated appeared to result in an intracellular concentration of PII remotely similar to that obtained from the single-copy gene at the normal chromosomal location. (Indeed, we used a plasmid system that hyperexpressed PII to isolate a mutant PII unable to interact with NRII.) Thus, these alleles will have to be moved onto the chromosome in the normal context for in vivo analysis. Second, the fact that PII is partially redundant in E. coli and the present lack of a null mutation in the gene encoding the second PII confound the interpretation of results. Finally, during the long periods of growth under stressful conditions characteristically used for physiology experiments, suppressing mutations arise in the populations, potentially further confounding the interpretation of results. These issues were circumvented by direct analysis of the altered proteins. While we are certain of the sequence of each allele cloned into the pJLA503 vector used for overexpression, there remains no guarantee that additional mutations were not acquired during the growth of cultures for protein preparation. However, the pJLA503 vector system that we used for overexpression of PII seemed to be well repressed under the noninducing conditions, as deduced by the very poor complementation of a strain with a glnB deletion by pJLA503 containing glnB ϩ . Thus, additional mutations in the plasmid-borne glnB alleles should have little selective advantage in this expression system. We used strain BD (⌬glnB glnD99::Tn10) to overexpress the proteins. Previous characterization of this strain indicated that it does not contain detectable GlnK protein, regardless of growth medium (51) . Physiology and genetic experiments, however, indicate that there must be some of the GlnK protein present under these conditions (8; reviewed in reference 36). Nevertheless, given the massive overproduction of PII in the cells used for PII purification here, there should be little contamination of our protein preparations with GlnK. Also, previous characterization of glnD99::Tn10 indicated that the allele does not behave as a null mutant (4, 6); rather, the strain behaved as if a low level of PII uridylylation and deuridylylation could occur. We grew the cultures for protein purification under conditions of extreme nitrogen excess to minimize the uridylylation of PII by the glnD99::Tn10 product. These growth conditions should result in little modification of PII, even in a glnD ϩ background. Gel electrophoretic analysis of our purified PII proteins (not shown) indeed indicated that they were unmodified.
In this study, the interaction of each mutant PII protein with its receptors was measured in activity assays. These methods alone cannot distinguish between defects in binding the receptor and defects in eliciting the measured activity. With regard to the UTase activity, we were able to make further distinctions as to the nature of the PII defects by examining the ability of altered PII proteins to inhibit the uridylylation of wild-type PII (Fig. 5) or, in the case of the E50Q protein, by determining the K m and k cat values for the mutant PII protein and comparing these to the values previously obtained for wild-type PII. These studies indicated that the E50Q, Y51F, and Y51F Y46F proteins interact with the enzyme, whereas the G89A and ⌬47-53 altered PII proteins essentially do not. With regard to the regulated phosphatase activity, we measured the ability of the altered PII proteins to elicit this activity of NRII when present at a high (3.0 M) and a low (0.3 M) concentration. While many of the altered proteins were subtly defective in eliciting this activity when present at the low concentration, all of these retained the ability to elicit the regulated phosphatase activity at wild-type levels when present at the high concentration (Table 2 ). This suggests that these altered PII proteins were mainly defective in binding to NRII. In three cases (A49P, G89A, and ⌬47-53), the altered PII proteins could not stimulate the regulated phosphatase activity even when present at high concentrations, which could have been due to either a complete inability to bind to NRII or a complete inability to elicit the regulated phosphatase activity. In unpublished studies, we examined the binding of each altered PII to NRII by the surface plasmon resonance method (20) , and the results of those studies suggested that these three altered PII proteins could not bind to NRII (25) .
In several instances our data set permits the assessment of internal consistency. For example, we measured the ability of NRII (10 M) to stimulate the binding of 2-ketoglutarate by PII and measured the ability of PII to activate the regulated phosphatase activity. The results were all in concordance. Also, we measured the binding of 2-ketoglutarate at low concentrations and the ability of 2-ketoglutarate at high concentrations to stimulate the binding of ATP. When 2-ketoglutarate binding was ϳ15% that of the wild type in the first of these assays, this was sufficient to permit the stimulation of ATP binding by 2-ketoglutarate at a high concentration. One minor inconsistency was observed in the case of the Q39E protein; this protein essentially did not bind 2-ketoglutarate in the direct assay, yet 2-ketoglutarate was able to bring about a slight stimulation of the binding of ATP. Thus, this protein is certainly defective in 2-ketoglutarate binding but perhaps does not completely lack this capacity. Another test for internal consistency is obtained by comparing the ability of the PII proteins to bind the small molecule effectors and the ability to become uridylylated or activate the regulated phosphatase. Previous work has indicated that the small-molecule effectors are absolutely required for the UTase interaction and greatly stimulate the interaction with NRII; thus, mutants that do not bind effectors should not work with these receptors. All of our mutant proteins obey this rule.
The interactions of PII with its receptors were genetically separable. The main conclusions from Table 2 are that the mutations affect each interaction of PII in a variable way and, thus, that the interaction of PII with its protein receptors is subtly distinct and genetically separable. For example, the A49P alteration, selected genetically as defective in the interaction with NRII, proved to eliminate the interaction with NRII while having a modest or no effect on the other activities of PII. The G41A mutations selectively eliminated the interaction of PII with UTase/UR, while the G84A mutation eliminated the interaction of PII with the ATase while retaining considerable ability to interact with NRII and UTase/UR. In other cases, the interactions with two of the three protein receptors were diminished by mutation. For example, the G37A protein retained the ability to interact with UTase/UR, and the V53G protein retained the ability to interact with NRII. Thus, the interactions of PII with its three receptors are different. Below, the results for each mutation are summarized and discussed with reference to the site of mutation within the PII trimer.
(i) T29M. This residue is in ␤2, near the subunit interface, on the rim of the central channel. The side chain projects from the surface, and may be exposed, peaking beyond the edge of helix A. Carr et al. (9) report that it is hydrogen bonded with E62, whose side chain points into the central cavity. The mutation of T29 to M was selected as causing the inability to activate glnA transcription in response to nitrogen limitation; the protein showed a general defect in all functions of PII, with the NRII interaction affected least. Since the selection scheme utilized a plasmid that overexpressed PII, such mutants are not unexpected. This mutation may cause a subtle distortion of the whole structure.
(ii) G37A. This residue forms a turn at the base of the T-loop, at the junction of ␤2 and the T-loop, where it is nestled between the L45 and the L56 side chains. The side chain of adjacent F36 also abuts the L45 side chain. A side chain at this position would perhaps alter the positions of the R38 or L45 side chains. The mutation resulted in a defect in 2-ketoglutarate binding and the interaction with all three protein receptors, with the UTase/UR interaction affected least. These effects may be indirect and be due to general distortion of the T-loop or distortion of the position of the R38 side chain, which lines the cleft formed by all three loops.
(iii) R38H. This site is at the base of the T-loop, but the R38 side chain points out near the B-loop, lining the cleft formed between subunits by the T-, B-, and C-loops (9, 10) . Since the side chain is on the surface, this side chain may participate in regulatory interactions. The side chain projects towards K90, at the B-loop-␤4 junction, and packs against I86 (9) . The mutation resulted in a modest defect in ATP and UTase interactions, while the interactions with NRII and ATase were unaffected. These modest effects may be due to subtle alterations in the structure of the T-loop and/or the cleft lined by T-, B-, and C-loop residues.
(iv) Q39E. The glutamine side chain at this position is probably involved with stabilizing the T-loop conformation; the side chain projects into the core of the T-loop, and the amide nitrogen protrudes on the other side of the T-loop between the L56 (␤3) and H42 (T-loop) side chains. The site is close to a prominent kink in the T-loop, and the Q39 residue may play an important role in stabilizing the T-loop structure. The mutation to glutamate severely diminished the interactions with UTase/UR, NRII, and 2-ketoglutarate and had a less severe effect on the interactions with ATase and ATP. These effects are likely due to alterations in the T-loop and the cleft formed between B-, C-, and T-loops.
(v) K40N. Although the site is in the T-loop, the side chain at this site lines the cleft formed between the T-, B-, and C-loops, as does that of R38 (9) . The closest approach of this side chain to the B-loop is about 7 Å. The mutation to asparagine dimished the interaction with all three protein receptors. Binding of 2-ketoglutarate was wild type, but the interaction with ATP was modestly reduced. These effects may be due to alteration of the T-loop or the cleft formed between the B-, C-, and T-loops.
(vi) G41A. This site, within the T-loop, is on the surface near the prominent kink in the T-loop. A side chain at this position would probably pack against that of H42 and project from the surface, possibly distorting the position of the K40 side chain. Mutation of this site to alanine resulted in a severe and very specific defect in the interaction with UTase/UR. This effect may be due to subtle alteration of the T-loop or the cleft formed between B-, C-, and T-loops.
(vii) Y46F. The tyrosine side chain lies on the surface of the T-loop, but the phenolate oxygen atom is about 15 Å from the active-site (Y51) phenolate oxygen. The side chain forms part of the hydrophobic "neck" of the T-loop and may contribute directly to receptor interactions. Mutation of this site to phenylalanine resulted in no alteration in small-molecule effector interactions but a modest defect in the interactions with all three protein receptors. These effects may be due to a direct role in receptor-PII contacts.
(viii) A49P. This residue forms part of the tight turn at the apex of the T-loop. The side chain is sandwiched between G48 and E50, whose side chain is extended away from the surface, and is about 3.2 to 4.5 Å from the side chain of M52. It is hard to predict if effects of the mutation to proline are due to distortion of the chain or steric interference with the side chain of M52 or both. The mutation to proline resulted in a severe and very specific defect in the interaction with NRII. In addition, this protein bound 2-ketoglutarate better than the wild type. This most likely results from alteration of the T-loop structure.
(ix) E50Q. This site, adjacent to the active site Y51, is at the apex of the T-loop. The side chain extends from the surface and is bent slightly away from the plane of the adjacent tyrosine ring, such that the distance between the phenolyate oxygen and glutamate oxygens is ϳ5.3 Å. Mutation of this site to glutamine had a severe and highly specific effect on the catalysis of the uridylyltransfer reaction; the interaction with UTase/UR, the other protein receptors, and the small-molecule effectors were unaffected. Thus, the glutamate side chain is not required for recognition by any of the receptors or interaction with the small-molecule effectors. Holtel and Merrick (18) isolated a mutated PII K. pneumoniae that caused alteration of E50, and based on physiological studies it was proposed that the mutation prevented PII uridylylation but not the interaction with NRII. Our results confirm that assessment.
(x) Y51F. This residue is the active site for the uridylyltransfer reaction and is completely exposed on the surface. Mutation of this site to phenylalanine completely eliminated uridylylation of PII, indicating that no other site on PII may substitute for it, and also diminished the interactions with NRII and the ATase. These effects are likely due to direct interaction of the receptors with this part of PII. In earlier studies, mutations affecting this site were not obtained in mutant searches seeking a specific defect within uridylylation (17) . Our results indicating that alteration of this site also severely affected the interaction with NRII may explain this.
(xi) V53G. This site, on the surface of PII at the base of the T-loop, plays an important role in loop conformation and may have a role in interactions. The side chain packs against the side chain of F55, serving to support the T-loop. A smaller side chain would likely permit greater T-loop flexibility. Also, the greasy surface formed by V53 and F55 side chains may have a docking function. The nearby L45 and F36 side chains extend the greasy collar around the base of the T-loop. The mutation V53G mostly affected the interactions with the UTase/UR and ATase. These effects may be due to direct interaction of the V53 side chain with the receptors or be due to changes in the conformation of the T-loop.
(xii) R79H. This site is on the surface of ␣B, with the arginine side chain extending from the surface near where helix B is packed against helix A. Mutation of this site to histidine had essentially no effect. This is reasonable, as this part of PII is not highly conserved and probably is not involved in any of the interactions studied here.
(xiii) T83N. This site is in the B-loop, near the site where ␤1 joins ␣A. The distance from F11 (␣A) is about 4 Å, that from L9 (␤1) is about 4.7 Å, and that from D88 (B-loop) is about 2.6 Å. The T83 side chain packs between the B-loop and the rest of protein. Mutation of this site to asparagine was selected in vivo, like the T29M mutation, as defective in the UTase/UR interaction. The mutant T83N protein proved to be defective with all protein receptors but was least defective with NRII. The protein was also defective in ATP binding in the absence of 2-ketoglutarate. These defects may result from perturbation of the structure of the B-loop and surrounding parts of the protein.
(xiv) G84A. The glycine at this position forms a tight turn at the base of the B-loop. It appears that a side chain at this position would project from the surface between the side chains of K90, R38, and Q82, distorting their positions. Mutation of this site to alanine resulted in a severe defect in the interaction with ATase and a less severe defect in ATP binding in the absence of 2-ketoglutarate. It seems that these effects may be due to an altered B-loop or the cleft formed between the B-, C-, and T-loops.
(xv) G89A. This site is located where the B-loop joins sheet 4, on the surface. A side chain at this position would project into the monomer, against I7 of ␤1. G89 forms the tight turn between the B-loop and K90, which lines the cleft between the T-, B-, and C-loops. Mutation of this site to alanine essentially eliminated all functions of PII. The inability of this protein to interact with the protein receptors may be a secondary effect of the defect in the ability to bind the small-molecule effectors. These effects may result from an alteration in the conformation of the B-loop or the position of the K90 side chain.
(xvi) K90R. The K90 side chain lines the cleft formed between the C-, B-, and T-loops (9) . The side chain is about 4 Å from the R38 side chain. Mutation of this site to arginine resulted in a protein defective in ligand binding and the interaction with all three receptors, with the interaction with NRII being least defective. Like the G89A protein, the defects in interactions with the receptors may be due to the defect in the ability of this protein to bind the small-molecule effectors.
(xvii) ⌬47-53. This protein, missing the apex of the T-loop and undoubtedly differing in conformation from the wild-type in surrounding regions as well (at least), was defective in all protein receptor interactions but bound the small-molecule effectors fairly well. This indicates that effector binding does not require contacts with any of the missing side chains.
Mapping functions onto the surface of PII. Structural studies have predicted that the T-loop and the cleft formed between the T-, B-, and C-loops are the sites of important regulatory interactions (9, 10) . Our results are in agreement with this hypothesis. With the exception of the T29M mutation, mutations affecting 2-ketoglutarate binding (G37A, R38H, Q39E, G89A, K90R) and ATP binding (G37A, R38H, Q39E, K40N, T83N, G84A, G89A, K90R) can all be expected to distort the cleft formed between the T-, B-, and C-loops, while mutations affecting the apex of the T-loop (⌬47-53, Y51F, E50Q, A49P) had relatively minor effects on the binding of the small-molecule effectors but could have profound effects on receptor specificity. However, G84A, a mutation mapping in the B-loop, could also alter receptor specificity (eliminating the interaction with the ATase). Thus, at this point a reasonable hypothesis for the regulation of the interactions of PII is that the small-molecule effectors bind in the cleft formed between the T-, B-, and C-loops and that this binding alters the conformation of the apex of the T-loop, activating the interactions with receptors. This hypothesis may be critically examined by characterizing mutant forms of PII containing substitutions at different sites and different substitutions at the sites examined in this study and by structural studies of the complexes formed between PII and its small-molecule effectors and receptors.
